BioNTech SE Announces CSO Ryan Richardson's Departure

TL;DR

BNTX CSO Ryan Richardson is out, effective July 17, 2025. Watch for strategic shifts.

AI Summary

On July 17, 2025, BioNTech SE announced that Ryan Richardson will be stepping down from his role as Chief Strategy Officer. The company filed a Form 6-K to report this change.

Why It Matters

The departure of a Chief Strategy Officer can signal shifts in a company's strategic direction or operational focus, potentially impacting future growth and partnerships.

Risk Assessment

Risk Level: low — This filing is a routine announcement of an executive departure and does not contain information about financial performance or significant operational changes.

Key Players & Entities

• BioNTech SE (company) — Registrant
• Ryan Richardson (person) — Chief Strategy Officer
• July 17, 2025 (date) — Announcement Date
• 001-39081 (company) — SEC File Number
• Nasdaq: BNTX (company) — Stock Ticker

FAQ

From the Filing

0001776985-25-000045.txt : 20250717 0001776985-25-000045.hdr.sgml : 20250717 20250717083253 ACCESSION NUMBER: 0001776985-25-000045 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250717 FILED AS OF DATE: 20250717 DATE AS OF CHANGE: 20250717 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 251128961 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kcsoannouncement17ju.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JULY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On July 17, 2025, BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced that Ryan Richardson will step down as Chief Strategy Officer in the Management Board of BioNTech on September 30, 2025, and as a Board Director at affiliated companies of the BioNTech Group by mutual agreement to pursue new professional opportunities. The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Ramón Zapata-Gomez By: /s/ Dr. Sierk Poetting Name: Ramón Zapata-Gomez Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: July 17, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Announces Ryan Richardson to Step Down from the Management Board EX-99 2 a991250717_bntxxprxrrxenxf.htm EX-99 Document Exhibit 99.1 BioNTech Announces Ryan Richardson to Step Down from the Management Board MAINZ, Germany, July 17, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Ryan Richardson will step down as Chief Strategy Officer in the Management Board of BioNTech on September 30, 2025, and as a Board Director at affiliated companies of the BioNTech Group by mutual agreement to pursue new professional opportunities. The process of transitioning his responsibilities to other members of the Management Board is underway, ensuring a smooth handover. Ryan Richardson joined BioNTech in 2018 and has served as Chief Strategy Officer since January 2020. During his time at the Company, he contributed significantly to BioNTech’s successful development, including its Series B financing, the Initial Public Offering on Nasdaq, and subsequent private placement and follow-on equity financings, which together raised more than USD 1 billion in capital. In addition to building Global Strategy and Corporate Development functions which supported BioNTech&#821